Amele S, Peters L, Rodger A, et al. - Researchers here analyzed data of all HIV/HCV coinfected individuals in the EuroSIDA study that initiated treatment with interferon free direct-acting antivirals (DAAs) with the aim to determine the efficacy, safety, and reasons for premature discontinuation of DAAs in this population. Of 1,042 individuals initiating interferon-free DAA treatment, 862 (82.2%) had a known response to treatment, and 789 achieved sustained virological response (SVR), defined as a negative HCV-RNA result ≥ 12 weeks after stopping treatment (SVR12). Individuals that received sofosbuvir/simeprevir ± ribavirin (RBV) or ombitasvir/paritaprevir/dasabuvir ± RBV exhibited lower odds of achieving SVR12 vs those receiving sofosbuvir/ledipasvir ± RBV. Early termination of one or more components of the HCV regimen was noted in 43 (4.6%) individuals, most due to toxicity (n = 14); of these, 11 were treated with ribavirin. The most common grade 3 or 4 laboratory adverse event was increased bilirubin (n = 15.3%), which was noted to be related to treatment with atazanavir and ribavirin. Overall findings suggest that, in all regions of Europe, DAA treatment is well tolerated and high rates of SVR12 can be achieved.